Conversely, in breast, melanoma, brain, colon, prostate, kidney, esophageal, lung, and pancreatic cancers, SPARC expression has been associated with a more aggressive phenotype, inhibiting apoptosis and promoting tumor invasiveness and metastases [2]. This evidence concerns the gene SPARC and neoplasm.